Home›Insulin Glargine

Insulin Glargine

Also known as: Basaglar Kwikpen, Basaglar Tempo Pen

Insulin Analog

Route: Subcutaneous

Check Insulin Glargine Interactions →
40 interactions on record

Insulin Glargine has 40 known drug interactions based on U.S. FDA drug labeling data. 22 are classified as major interactions requiring close medical supervision. Notable interactions include combinations with Albuterol, Clozapine, Corticosteroids. Patients taking Insulin Glargine should inform their healthcare provider of all current medications — including over-the-counter drugs and supplements — to avoid potentially harmful combinations. Data sourced from OpenFDA and the NIH National Library of Medicine.

Total
40
Major
22
Moderate
16

Major (22)

  • Insulin Glargine + Albuterol— May decrease blood glucose lowering effect of LANTUS. Dosage increases and increased glucose monitoring may be required.
  • Insulin Glargine + Clozapine— May decrease blood glucose lowering effect of LANTUS. Dosage increases and increased glucose monitoring may be required.
  • Insulin Glargine + Corticosteroids— May decrease blood glucose lowering effect of LANTUS. Dosage increases and increased glucose monitoring may be required.
  • Insulin Glargine + Danazol— May decrease blood glucose lowering effect of LANTUS. Dosage increases and increased glucose monitoring may be required.
  • Insulin Glargine + Disopyramide— May increase risk of hypoglycemia. Dosage reductions and increased glucose monitoring may be required.
  • Insulin Glargine + Diuretics— May decrease blood glucose lowering effect of LANTUS. Dosage increases and increased glucose monitoring may be required.
  • Insulin Glargine + Epinephrine— May decrease blood glucose lowering effect of LANTUS. Dosage increases and increased glucose monitoring may be required.
  • Insulin Glargine + Estrogens— May decrease blood glucose lowering effect of LANTUS. Dosage increases and increased glucose monitoring may be required.
  • Insulin Glargine + Fibrates— May increase risk of hypoglycemia. Dosage reductions and increased glucose monitoring may be required.
  • Insulin Glargine + Fluoxetine— May increase risk of hypoglycemia. Dosage reductions and increased glucose monitoring may be required.
  • Insulin Glargine + Glucagon— May decrease blood glucose lowering effect of LANTUS. Dosage increases and increased glucose monitoring may be required.
  • Insulin Glargine + Isoniazid— May decrease blood glucose lowering effect of LANTUS. Dosage increases and increased glucose monitoring may be required.
  • Insulin Glargine + Niacin— May decrease blood glucose lowering effect of LANTUS. Dosage increases and increased glucose monitoring may be required.
  • Insulin Glargine + Octreotide— May increase risk of hypoglycemia. Dosage reductions and increased glucose monitoring may be required.
  • Insulin Glargine + Olanzapine— May decrease blood glucose lowering effect of LANTUS. Dosage increases and increased glucose monitoring may be required.
  • Insulin Glargine + Pentoxifylline— May increase risk of hypoglycemia. Dosage reductions and increased glucose monitoring may be required.
  • Insulin Glargine + Phenothiazines— May decrease blood glucose lowering effect of LANTUS. Dosage increases and increased glucose monitoring may be required.
  • Insulin Glargine + Pramlintide— May increase risk of hypoglycemia. Dosage reductions and increased glucose monitoring may be required.
  • Insulin Glargine + Salicylates— May increase risk of hypoglycemia. Dosage reductions and increased glucose monitoring may be required.
  • Insulin Glargine + Somatropin— May decrease blood glucose lowering effect of LANTUS. Dosage increases and increased glucose monitoring may be required.
  • Insulin Glargine + Terbutaline— May decrease blood glucose lowering effect of LANTUS. Dosage increases and increased glucose monitoring may be required.
  • Insulin Glargine + Thyroid Hormones— May decrease blood glucose lowering effect of LANTUS. Dosage increases and increased glucose monitoring may be required.

Moderate (16)

Insulin Glargine + Acetazolamideℹ️Unknown

7 DRUG INTERACTIONS Table 6 includes clinically significant drug interactions with BASAGLAR Table 6: Clinically Significant Drug Interactions with BASAGLAR Drugs That May Increase the Risk of Hypoglycemia Drugs: Antidiabetic agents, ACE inhibitors, angiotensin II receptor blocking agents, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, pentoxifylline, pramlintide, salicylates, somatostatin analogs (e.g., octreotide), and sulfonamide antibiotics. Drugs that may increase the risk of hypoglycemia: antidiabetic agents, ACE inhibitors, angiotensin II receptor blocking agents, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, pentoxifylline, pramlintide, salicylates, somatostatin analog (e.g., octreotide), and sulfonamide antibiotics ( 7 ).

Insulin Glargine + Somatostatinℹ️Unknown

7 DRUG INTERACTIONS Table 6 includes clinically significant drug interactions with BASAGLAR Table 6: Clinically Significant Drug Interactions with BASAGLAR Drugs That May Increase the Risk of Hypoglycemia Drugs: Antidiabetic agents, ACE inhibitors, angiotensin II receptor blocking agents, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, pentoxifylline, pramlintide, salicylates, somatostatin analogs (e.g., octreotide), and sulfonamide antibiotics. Drugs that may increase the risk of hypoglycemia: antidiabetic agents, ACE inhibitors, angiotensin II receptor blocking agents, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, pentoxifylline, pramlintide, salicylates, somatostatin analog (e.g., octreotide), and sulfonamide antibiotics ( 7 ).

Data sourced from U.S. FDA drug labeling via openFDA and the NIH National Library of Medicine, supplemented with a small number of well-established interactions from curated clinical references. For informational purposes only. Always consult your pharmacist or physician.

CDI: source-linked explanations